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Platelet cationic proteins are present in glomeruli of lupus nephritis
patients. Synthetic polycations have been shown to bind and neutralize
glomerular polyanions (GPA), thereby increasing the permeability of
the glomerular capillary wall (GCW). In the present study it is demon-
strated that human platelet—derived cationic proteins (HuPIt CP), which
are able to increase cutaneous vascular permeability, bind in vitro to the
GCW following incubation of normal human kidney sections with
purified HuPIt CP or with washed human platelets stimulated with
thrombin, immune complexes (IC) and platelet—activating factor (PAF),
or stimulated with a suspension of washed human platelets and poly-
morphonuclear leukocytes in the presence of phagocytable substrate.
The antiserum used in immunofluorescence test to detect the binding of
HuPIt CP was specific for two different molecular types of HuPlt CP,
both with an isoelectric point (p1) of 10.5. Glomerular deposits of HuPlt
CP were also detectable by immunofluorescence microscopy in renal
glomeruli present in tissue obtained by biopsy from patients with
systemic lupus erythematosus (SLE), a disease in which platelets have
been implicated as mediator of glomerular injury. These data indicate
that when activated platelets release HuPIt CP in vivo, these proteins
bind to glomerular structures. The binding of HuPIt CP to GCW appears
to be ionic in nature since heparin, a polyanion, prevents this binding in
vitro. In addition, heparin, as well as a high molarity buffer, removed
deposits of HuPit CP bound in vitro to normal GCW or bound in vivo
to glomeruli of patients with SLE. The binding of HuPIt CP to GCW is
associated with loss of colloidal iron staining, a qualitative technique
that demonstrates primarily epithelial cell surface anionic sialoglyco-
proteins. In experiments of in vitro binding of purified HuPit CP to
section of normal kidney treatment with heparin completely restores
the normal pattern of colloidal iron staining suggesting ionic neutraliza-
tion of GPA. In contrast, heparin is only partially effective in restoring
colloidal iron staining in normal kidney sections treated with platelets
directly stimulated with IC or PAF or in kidney sections of patients with
SLE. These observations indicate that under these conditions the ionic
interaction of HuPtt CP with GCW is only partially responsible for the
loss of colloidal iron staining. The results of the present study suggest
that biologically active polycationic mediators released from stimulated
platelets localize in GCW and participate in the induction of glomerular
injury.
Several lines of evidence indicate that platelets may have a
pathogenic role in the induction of glomerular injury [1, 2]. In
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vitro, several substances implicated in the expression of gb-
merulonephritis, such as immune complexes (IC) in antibody
excess and platelet—activating factor (PAF), are capable of
activating platelets [21. In vivo, a shortened platelet survival or
an intrarenal sequestration of platelets has been shown in
several human glomerular diseases [3—5]. In addition, constitu-
ents of platelet granules such as platelet factor 4 (PF4) and
serotonin are elevated in the plasma of patients with glomeru-
lonephritis [6, 7]. By immunofluorescence microscopy, the
presence of undefined platelet antigens and of PF4 within
glomerular structures has been described in several forms of
glomerulonephritis [8, 9]. PF4, a cationic (p1 7.6) platelet
secretory protein, binds avidly to glomerular polyanions (GPA)
both in vitro and in vivo following intravenous injection into
rats [10]. Besides PF4, platelets contain a number of other
cationic secretory proteins (p1 9.5 to 10.5) with defined biologic
activities [2]. The vascular permeability factor described by
Nachman et al [111 is a strongly cationic component that is able
to increase vascular permeability in the skin and induce a local
inflammatory reaction. Other platelet derived cationic proteins
(Plt CP) have been shown to possess chemotactic, mitogenic
and enzymatic activities [2].
Since the glomeruiar basement membrane contains fixed
anionic sites which confer an overall negative electric charge to
this structure [12—14], PIt CP may be expected to bind to
glomerular capillary walls (GCW). Based on data derived from
synthetic polycations [15, 161 it seems likely that PIt CP may
alter the polyanionic properties of the GCW and thereby
enhance its permeability. In addition, based on their biologic
activities in vitro [2], it has been suggested that Plt CP recruit
inflammatory cells, and stimulate the proliferation of resident
glomerular cells, thus contributing to the expression of glomer-
ular injury. However, to date none of PIt CP has been shown to
bind to the GCW, enhance GCW permeability, or induce an
inflammatory reaction. The aim of the present study was to
determine whether: 1) human Pit CP (HuPIt CP) bind in vitro to
structures of normal human renal cortex as a consequence of
ionic interaction, and 2) whether glomerular deposits of HuPIt
CP are detectable by immunofluorescence microscopy in renal
tissue obtained by biopsy from patients with systemic lupus
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erythematosus (SLE), a disease in which platelets have been
implicated in the pathogenesis of glomerular injury 1171.
Methods
BuJfrrs
The composition of buffers used was as follows: Tyrode's
(T): KCI, 2.6 mM; MgCI26H2O, 1 msi; NaCl, 137.0 mM;
NaHCO3, 10.0 mM; CaCI76H,O, 1.3 mM; glucose, 0.1%.
Tris—buffered Tyrode's (TT), Tyrode's with fris (hydroxy-
methylaminomethane), 1.0 m, was used instead of bicarbon-
ate. When TT was used in the preparation of purified, washed
human platelets and PMN, phenyl methyl sulphonyl fluoride (1
mM, PMSF, Calbiochem—Behring Co., La Jolla, California,
USA), aprotin (100 U/mI, Trasylolk, Mayer italia S.P.A.,
Milano, Italy), both inhibitors of proteases [26, 27], and
ethylene diamine tetraacetate (EDTA, 1 mM), a calcium ligand.
were added. When indicated, 0.25% bovine serum albumin
(BSA, Fraction V. Eurobio, Paris, France) was added to TT
(TT-BSA). When calcium and magnesium were omitted in TT,
the latter was designated as Ti' no Ca2 no Mg2. Phosphate
buffered saline (PBS) consisted of 0.1 M phosphate buffer
supplemented with 0.15 M NaCI. Unless otherwise stated, all
buffers were adjusted to pH 7.4.
Stimuli
The following agents were used to stimulate human platelets:
thrombin (Hoffman—La Roche, Diagnostica Division, Basel,
Switzerland), IC (BSA-rabbit lgci anti-BSA) in twentyfold
antibody excess, prepared as detailed in a previous article [18],
synthetic l-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcho-
line (synthetic platelet—activating factor, PAF) (Bachem Fein-
chemikalien AG, Bubendoi-f, Switzerland) dissolved as stock
solution in chloroform—methanol (2:1, vol/vol. 1 mg/mI) and,
before use, in 0.25% BSA containing isotonic saline, with BSA
as a PAF carrier [191. Characterization of PAF was based on the
following criteria: 1) ability to induce rabbit platelet aggrega-
tion, which was unaffected by indomethacin (10 m, Sigma
Chemical Company, St. Louis, Missouri, USA), and ADP
scavengers (creatine phosphate 312.5 ,ag/ml—creatine phospho-
kinase 152.5 tg/ml enzymatic system, Sigma) [301; 2) physico-
chemical characteristics [20] and migratory propel-ties on thin
layer chromatography (TLC) performed according to the tech-
nique of Pinckard, Farr and Hanahan [20]. In experiments using
washed human platelets and PMN mixed suspensions, lgG-
opsonized baker's yeast particles (lgG-BYP), prepared as de-
tailed in a previous article [18] and adjusted to a concentration
of 5 107/ml, were used to stimulate PMN.
Preparation of Cells
Fresh human blood was collected in siliconized 50 ml plastic
tubes, containing EJY1A (5 x 10 M, final concentration), pH
7.2. After centrifugation (350 g, 20 mm, 4°C), blood separated
into three layers; platelet—rich plasma, huffy coat, and PMN
plus erythrocytes. Platelets were prepared as previously de-
scribed [21] and washed three times in TT no Ca2 no Mg2
with intermediate centrifugations (1,000 g, 15 mm, 4°C), and a
final, low—speed (30 g, 15 mm) centrifugation in order to
eliminate contaminating leucocytes. Less than 0.01% leuco-
cytes were present in the platelet preparation. When platelets
were prepared for subsequent purification and characterization
of HuPIt CP [11, 22], PMSF, aprotin, and EDTA were added to
the washing and resuspending buffer. Ninety to 95% pure
human PMN were prepared as previously described 1181, from
the granulocyte—erythrocyte—containing sediment by subse-
quent gelatin sedimentation, osmotic shock, and finally washed
three times with TT no Ca2 no Mg2, supplemented with
PMSF, aprotin, and EDTA. Platelet contamination was less
than 1%.
Cells were either used in in vitro studies immediately after
preparation or pooled scparatively and kept frozen at —80°C in
distilled water.
Purification and characterization of IluPit C?
and PMN CP (NC?)
HuPII CP were obtained from platelets after sonication,
extraction of the lysosomal granules by diluted H,S04 and
lyophilization of the neutralized extracts according to Nach-
man, Weksler and Fabris [11]. Purification of HuPIt CP was
pci-formed by cation—exchange chromatography using CM-
Scpharose 4B, equilibrated with 0.05 M phosphate buffer p1-I
7.6. Elution of HuPIt CP was accomplished over a salt (NaCI I
M) gradient. Characterization of HuPlt CP was accomplished by
sequential chromatofocusing [231 and gel filtration by high
pressure liquid chromatography (HPLC). Chromatofocusing
was performed on a 1.6 x 40cm column packed with PBE 118
(Pharmacia Fine Chemicals, Uppsala, Sweden), equilibrated
with 25 mvt triethylamine-HCI, pH 10.7. Elution was carried
out with Pharmalyte (Pharmacia Fine Chemicals, 1:45, vol/vol)
pH 7.7, and four peaks were resolved at the following pH: 10.5,
8.5, 8.25. 8.0. The most cationic (pH 10.5) peak was applied to
a HPLC modular system consisting of a dual pump (112 Model,
Beckman instruments, San Diego, California, USA), and fitted
with a 0.75 >< 30 cm column (particle size: 10 m; G3000
SpherogelfM, Altex, San Diego, California, USA), which was
connected to a Unicord UV-detector (280 m, LKB, Lund,
Sweden). An Altex model 211) injector (Beckman) was fitted
with a 250 ,td sample loop, and normally a volume of 100 pi
would be applied. The column was equilibrated with acetate
buffer 10 mM, NaCI 0.15 M, 0.1% sodium dodecyl sulphate
(SDS) pH 4.0. Polyacrylamide gel electrophoresis (PAGE) was
performed in the presence of SDS as described in a previous
publication [18]. The peaks eluled from the HPLC column were
tested for their ability to induce cutaneous vascular permeabil-
ity in rabbits pretreatcd with Evans' Blue as described by
Nachman. Weksler and Fabris [Ill. The results were expressed
as the minimal concentration of HuPlt CP, giving a blucing area
of more than 5mm. The HuPIt CP preparations were also tested
for presence of PF4 by radioimrnunoassay [71.
NCP were obtained from sonicated PMN according to the
technique described in 1211, consisting in the separation of NCP
from the acid extracts by anion exchange chromatography and
gel filtration using sequentially DEAE and Sephadex G-100
(Pharmacia) columns. Human PF4 was purified by affinity
chromatography as previously described [241.
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Preparation and characterization of anti-HuP/t CP
and -NCP sera
The cationic components of human platelets and PMN were
separatively pooled and injected into a goat and a rabbit,
respectively [21, 221.
The specificity of the goat anti-HuPit CP was tested by a
radiometric assay, by immuno-precipitation on sodium dodecyl
sulfate—polyacrylamide gel electrophoresis (SDS-PAGE), and
by indirect or direct immunofluorescence microscopy tech-
niques on human peripheral blood smears and on normal human
kidney. The y-globulin fraction of the anti-HuPlt CP serum was
sequentially absorbed (30 mm at room temperature and at 4°C
overnight) with platelet—poor plasma Sepharose—immunoab-
sorbent prepared as described in [25], erythrocytes, purified
PMN, lymphocytes and plastic adherent mononuclear cells
prepared and pooled from eight normal donors, as previously
described [221.
The assessment of the specificity of the anti-HuPit CP serum
by a radiometric assay was performed as follows: HuPlt CP
were labeled with 125j following the technique by Greenwood
and Hunter modified by Malavasi et al [26]. 1251 HuPIt CP were
separated by HPLC as described above but in the absence of
SDS in the buffer system. Fifty—thousand cpm of each protein
peak were incubated for eight hrs with 50 l of goat anti-HuPlt
CP serum (1: 100 dilution). As control, we used non-immune
goat serum. Ten d of rabbit anti-goat serum were then added
and incubated for six hours. After this, the immune complexes
were precipitated by adding 100 d of 10% Staphylococcus
Aureus Cowan I (Bio-Yeda, Jerusalem, Israel) for one hour.
The pellets were washed three times with 15 ml of PBS-NaN3,
air dried and counted in a gamma counter (Packard Instruments
Co., Downers Grove, Illinois, USA). All the incubations were
performed at 4°C under constant shaking.
Further assessment of specificity of the goat antiserum raised
against HuPit CP was carried out by immunoprecipitating with
either 1251 labeled whole human platelet [27] extract (500,000
cpm) or '25I-HuPlt CP (50,000 cpm). Briefly, the dried pellets
were boiled for one minute in 10% SDS with or without
reduction by 2 beta—mercaptoethanol, and analyzed on vertical
slab gel [28] of 10% and 15% acrylamide for the whole human
platelet extract and HuPlt CP, respectively. Gels were fixed,
dried, and autoradiographed with an intensifying screen
(Cronex Lighting Plus, DuPont, Wilmington, Delaware, USA)
using Kodak X-RS films at —70°C (Eastman Kodak, Rochester,
New York, USA).
The y-globulin fraction of the anti-HuPlt CP serum was used
in indirect immunofluorescence microscopy tests or was conju-
gated with fluorescein isothiocyanate (Miles Laboratories,
Elkart, Indiana, USA), as described in a previous publication
[221 for studies of direct immunofluorescence microscopy. The
reactivity of anti-HuPIt CP was tested on human peripheral
blood smears and on normal human kidney as previously
described [22, 29]. In order to evaluate the specificity of the
binding to the cytoplasm of human platelets, a blocking test was
performed with antiserum absorbed with purified HuPit CP [22,
291.
The specificity of the rabbit anti-NCP serum has been de-
scribed in a previous publication [21].
Studies of in vitro binding of HuPIt ('P to normal
human kidney
Sections, 4 to 6 m in thickness of normal portions of human
kidney obtained at nephrectomy of eight patients with renal
cancer, snap—frozen in liquid nitrogen, were incubated for one
to 12 hours at 37°C in a moist chamber with 100 rg of HuPlt CP
in 0.1 M phosphate buffer, pH 7.4 or with purified human
platelets (100 d, 1-5 x l07/ml), obtained as described in the
Preparation of cells and stimulated in a moist chamber (37°C,
1—12 hr) with thrombin (0.5 U/mI), BSA-anti-BSA IC (250 g
antibody protein) and PAF (10b0 M) in TT-BSA with Ca2 and
Mg2 or with purified human platelets and PMN mixed suspen-
sions stimulated under the same experimental conditions as
described above with IgG-BYP (1 x 107/ml). In order to
evaluate the ionic interaction between HuPIt CP and the
glomeruli, sodium heparin (1 to 10 mg, LiqueminR, La Roche)
or PBS supplemented with NaCI 1 to 3 M were added to the
sections either concomitantly with, or 10 minutes after the
incubation with HuPlt CP or, in some experiments, after the
incubation with HuPIt CP and washing of the sections. The
binding of HuPit CP to normal human kidney was evaluated by
an indirect immunofluorescence microscopy test using an anti-
goat IgG serum (Behringwerke, Mannheim, FRG) in order to
amplify the fluorescence staining reaction for HuPit CP. In
preliminary experiments, the goat anti-rabbit IgG serum
preabsorbed with human y-globulin, was unable to stain renal
sections from normal as well as from SLE individuals. An
average of twenty glomeruli were examined with a Zeiss
Photomicroscope III, equipped with a HBO 75 W!2 high pres-
sure vapor lamp using a GB 12 exciter filter and a KV 49P
barrier filter (Zeiss, Oberkochen, FRG). The intensity of the
fluorescence staining was evaluated and graded from 0 to +3 by
two observers who were not aware of the experimental condi-
tions.
In order to evaluate the loss of GPA by light microscopy, the
colloidal iron staining [30], and as previously described by
Camussi et al [21] was performed before and after the incuba-
tion of formalin—fixed paraffin—embedded sections with HuPlt
CP, or after incubation with HuPlt CP followed by sodium
heparin (1 to 10 mg).
Patients
Fourteen patients (one male and 13 females), aged 19 to 65
years, satisfied the criteria of the American Rheumatism Asso-
ciation (ARA) for the diagnosis of SLE and were included in
this study[3l]. Patients with drug—induced, lupus—like or over-
lapping syndromes were not selected for this study. The clinical
activity was independently assessed at the time of the renal
biopsy by two investigators on the basis of the following signs
and symptoms [31]: fever, active rash, serositis, arthritis,
central nervous system involvement, and active renal disease.
As described in a previous publication [32], patients were
divided into three groups on the basis of the various degrees of
disease activity: Grade I (active) compromised patients with at
least three or more of the above—cited symptoms. In addition,
all of them had depressed C3 and C4 serum levels, high titers of
antinuclear antibodies [33] with a homogenous pattern, high
titers of anti-native DNA antibodies [34], and of circulating IC
[35, 36]). Furthermore, these patients had a leukopenia of less
than 4,000 white blood cells per cubic millimeter, while they
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were not exposed to drugs known to induce leukopenia. Grade
11 (moderately active) comprised patients with one or two of the
above—cited symptoms. Patients lacking any of these symptoms
or signs of serological SLE activity were assigned to Grade Ill
(inactive or in remission).
Eight normal human kidney specimens, and kidney needle
biopsies obtained from six patients with Berger's glomerulone-
phritis, and eight patients with minimal glomerular disease were
used as controls in the immunofluorescence microscopy and
histologic studies.
Histological and iminunopathological studies perfrmed on
renal tissues obtained by biopsy from patients with SLE
All fourteen patients with SLE nephritis were submitted to
percutaneous renal biopsy. The renal tissue was divided into
three parts (for light, electron, and imununofluorescence micros-
copy, respectively) and processed by standard techniques, The
histological findings were classified according to Appel et al [371
in five classes: class 1, normal kidney; class IT, mesangial
changes: class III, focal and segmental glomerulonephritis;
class IV, diffuse proliferative glomerulonephritis; class V,
membranous glomerulonephritis. For immunolluorescence
studies, sections were incubated with fluoresceinated rabbit
antisera specific for human IgG, 1gM, IgA, C3, Clq, C4 and
fibrinogen (Behringwerke). Serial sections were incubated with
anti-HuPII CP or anti-NCP sera using an indirect immunofluo-
rescence test as described in the In vitro studies and in a
previous publication [21]. A minimum of four glomeruli (range
4 to 23) were available. 'l'he intensity and extent of the fluores-
cence staining were evaluated independently and were graded
from 0 to +3 by two observers who were unaware of' the
pathologic findings. When staining for HuPIt CP or for NCP was
present, serial sections were incubated with the antisera previ-
ously absorbed with purified HuPIt CP or NCP, respectively, in
order to assess the specificity of the reaction. The presence of
GPA was evaluated by the colloidal iron staining technique [37]
as described by Camussi et al [211, in the same experimental
conditions outlined above in the section Studies of in vitro
binding of HuPit CF to normal hutnan kidney. As controls,
specimens from eight normal subjects, from six patients with
Berger's glomerulonephritis, and from eight patients with min-
imal glomerular disease were studied by the same techniques.
Results
Characterization of HuPlt CF and anti-IluPli CP serum
The acid extracts of human platelets contained a highly
cationic fraction (p1 = 10.5), as inferred from the pattern of
elution in cation—exchange chromatography (Fig. I) and in
chromatofocusing (Fig. 2). This fraction was mainly composed
of three molecular species with an apparent molecular weight of
55, 40 and 10 kd as determined by HPLC (Fig. 3) and of 60, 45,
15 kd by SDS-PAGE (not shown). The minimal concentrations
of 1-luPit CP giving an increased cutaneous vascular permeabil-
ity were 5.108 M, i.10 M and 1.10—10 M, respectively, for the
55, 40, and 10 kd fractions eluted from the HPLC column. None
of the HuPIt CP preparations contained a detectable amount of
PF4.
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Fig. 2. Elation pattern by chromato/wusing on a PBE 118 column (1.6
x 40 cm), equilibrated with 25 mM triethylamine-HCI, pH 10.7 of
pooled cationic components obtained from several runs of the
cation—exchange chromatography. The pH gradient was created with
pharmalyte (1:45, vol/vol), pH 7.7. Only the most cationic (p1 10.5)
component (peak 1) was pooled from several runs and used either for
further characterization by gel permeation in HPLC or as an antigenic
inoculum to immunize a goat.
The antiserum raised in a goat immunized with HuPIt CP
eluted from the chromatofocusing column was shown to be
specific for target proteins. The whole cationic preparation of
the human platelet acid extract was first labelled with 12S1
separated by HPLC in three molecular species, each of which
were then incubated with the antiserum. Using a radiometric
assay (Fig. 4), the antiserum immunoprecipitated the 55 kd and
40 kd but not the JO kd (not shown) cationic components. The
immunoprecipitates were shown by SOS-PAGE (Fig. 5), per-
formed in non-reducing (Fig. 5 A to C) and reducing (Fig. 5D to
F) conditions, to have a migration pattern (Fig. SB, C, E, F)
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Fig. 1. Cation-exchange chromatography on a CM-Sepharo.se 4B col-
umn (1.2 x 30 cm) qf a human platelet acid extract. Elution of the
cationic components (arrows) was performed on a salt (NaCI I M)
gradient in 0.05 phosphate buffer, pH 7.6.
Peak
2
I
40 80 120 160 180 200 ml
a)
a)
E
a)a
a)
(a
Cd,
a)>
a)
Ca
a)
a)
C.)C
Fig. 3. Gel permeation chromatograms by HPLC of (A) reference
molecular weights and (B) the most cationic (p1 10.5) component (peak
1) eluted from the chromatofocusing column: peak 1 = 55 kd; peak 2 =
40 kd; peak 3 = 10 kd. The lined area indicates the degree of the
permeability—enhancing activity of peaks eluted from HPLC and tested
at the concentration of 1.10-toM in the skin of rabbits preinjected with
Evans Blue (33): 0 = <1.15 mm, + = 1.5 to 3 mm, ++ = 5 to 12 mm
of blueing skin area at 15 mm after challenge.
Fig. 5. SDS-PAGE analysis of total '251-HuPlt CP (A, D) and of the
two major (60 kd, 45 kd) protein fractions BE C F, respectively) eluted
from the HPLC column (see Fig. 3), following immunoprecipitalion
with goat antiserum in (A—C) non-reducing and (D—F) reducing condi-
tions. Migration weight markers were lysozyine (14,400), soybean
trypsin inhibitor (21,400) carbonic anhidrase (31,000), ovalbumin
(45,000), BSA (66,200).
coincident with two (60 kd, 45 kd) of the HuPlt CP components
(Fig. A, D). In order to verify the ability of the antiserum to
specifically recognize the target proteins contained in the whole
human platelet extract, the latter was first labelled with 1251 and
then incubated with the antiserum. The immunoprecipitates
were analyzed by SDS-PAGE (Fig. 6). Two protein bands with
an apparent molecular weight of 60 kd and 45 kd (Fig. 6A, B)
were immunoprecipitated and their migration pattern was iden-
tical to that observed in the immunoprecipitation studies with
1251 FluPlt CP (Fig. 5B, C, E, F). Of interest, in the presence of
2-mercaptoethanol, as reducing agent (Fig. 6C, D), the protein
banding pattern of the 125! whole human platelet extract
changed, showing a fainter 45 kd band but a much more marked
15 kd moiety (Fig. 6C). In these conditions, a protein band with
an apparent molecular weight of 15 kd was also immunoprecip-
itated. These data may suggest the 45 kd fraction as a precursor
of the 15 kd moiety, the latter likely originating from hydrolysis
of disulfide bonds with the attendant unmasking of epitopes
reactive with the antiserum.
By direct and indirect immunofluorescence microscopy the
anti-HuPIt CP serum reacted with the cytoplasm of human
platelets. Absorption of this antiserum with purified HuPIt CP
abolished the reaction. No staining of human erythrocytes,
lymphocytes, or mononuclear cells in human peripheral blood
smears was observed. In addition, the antiserum did not react
with cells or basement membranes of normal human kidney.
By immunoprecipitation no reactivity of the anti-HuPlt CP
serum was detectable against normal human platelet—poor
plasma or purified human PF4.
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Fig. 4. Diagram of the radiometric assay of the two major protein
fractions (55 kd and 40 kd) of the cationic components eluted by HPLC
from the whole human platelet extract. A figure superior to three times
the background cpm was considered as positive score. 50,000 cpm of
each sample, corresponding to 0.5 sg and 5 jzg of the two 55 kd and 40
kd, respectively, were incubated with the goat antiserum. A non-
immune goat serum was used as control (C).
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Fig. 6. SDS-PAGE analysis of the '251-ii'liole hwnan platelet extract
irnmunoprecipit a/ed ui/li goal anti HuPit CI': lane a): si/to/c °51—JIoPlt
CI' extract under reductive and c) non—reductive conditions: lane h):
immunoprecipitated '251—protcin fraction from the whole platelet ex-
tract tinder reductive and ci) non—reductive conditions. Migration weight
markers were the same as in Figure 5, except for phosphorilase B
(92,500) instead of lysozyme.
Studic,s of itt vitro bittding of IltiPil CP to normal
humctn kidney
In the in vitro studies (Table 1, Fig. 7), HuPlt CP bound to
GCW, to the mesangium, and to the peritubular capillaries (Fig.
7 A). Heparin, a polyanion, but not aprotin, a protease inhibitor
[381, abolished the binding when added on the sections simul-
taneously with HuPlt CP. Furthermore, heparin, when added
after HuPIt CP, was able to dote HuPIt CF from their glomer-
ular binding sites. HuPIt CP were released and bound to GCW
after platelet stimulation directly on the sections by thrombin,
BSA-anti-BSA IC, and, particularly, by PAF or in the presence
of IgO-BYP activated PMN (Table I). The binding of HoPIt CF
to GCW (Fig. 7A) was associated with a marked reduction of
the colloidal iron staining (Fig. 7B and C), a qualitative tech-
nique that demonstrates GPA. A normal pattern of colloidal
iron staining could be restored after incubation with heparin
(Fig. 7D), hut not with aprotin (Table I). However. heparin only
partially restored the colloidal iron staining after direct platelet
stimulation with IC or PAF (Table I). Similar results were
obtained when, instead of heparin. a high ionic strength buffer
(PBS with NaCl 1 to 3 vi) was used (data not shown).
Table I. In vitro studies, binding of HuPIt CP to GCW and reduction
of colloidal iron staining in glomeruli present in sections of normal
human kidney
l.ight microscopy
reduction of
colloidal iron
Immunofluorescence staining--
Anti-t-tuPlt CP5 total Segmental
Satine alone 0 0/20 0/20
Purilied HuPIt CP 3 13/20 7/20
Puritied HuPIt CP + 0 0/20 2/20
heparin
Purified HuPIt CP + + 3 12/20 5/20
aprotin
Washed human platelets 0 0/20 0/20
alone
Washed human platelets + 1 1/20 9/20
+ thrombin
Washed human platelets + 1 12/20 5/20
+ BSA-anti-BSA
Washed human platelets 0 6/20 1/20
+ BSA-anti-BSA +
heparin
Washed human platelets +2 15/20 5/20
+ PAF
Washed human platelets 0 5/211 8/20
+PAF + heparin
Washed human platelets + 3 6/20 11/20
+ PMN -F IgU-BYP
These results are representative of four different sets of expen-
mcnts.
The binding of HuPIt CP to GCW was elevated by indirect im-
monofluorescence using a goat anti-HuPIt CP serum and a rabbit
anti-goat tgG serum, as second layer.
The colloidal iron staining (36), performed as described by Camussi
et al. (18) was used to elevate by light microscopy the loss of GPA.
Results were expressed as number of glomeruli with either total or
segmental loss of UPA on total number of glomeroli.
Histological anti itrttnunopathoiogicoi studies of renal tissue
obtained by' biopsy from patients with SLE
In the studies on renal biopsies (Table 2), deposits of CP
antigens that had hound in vivo were detectable in 12 (for HuPit
CP) and in nine (for NCP) out of 14 renal biopsies from patients
with SLE glomcrulonephritis. The specificity of the immuno-
fluorescence staining was confirmed by the loss of the reaction
after preabsorption of the anti-HuPIt CP and anti-NCP sera with
purified HuPlt CF and NCP, respectively. The deposits of
HuPIt CP were localized segmentally in the peripheral GCW
(Fig. 8). Both the intensity and extent of HuPIt CP deposits
were greater in the glomeruli of patients with grade I of SLE
activity, were more marked than for NCP deposits, and did not
correlate with the histologic class (Table 2). Regardless of the
histologic class, the presence of platelets in the lumen of
glomerular capillaries was detected by electron microscopy in
six patients who had glomerular deposits of HuPIt CP. The
reduction of colloidal iron staining appeared even more pro-
nounced in patients with severe proteinuria and nephrotic
syndrome. However, the reduction of colloidal iron staining
appeared more widespread than the deposits of HuPIt CP and
NCP (Fig. 9). In several biopsies, heparin could abolish the
immunofluorescent staining and restored the normal pattern of
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C3, Clq, C4, and fibrinogen (F) were evaluated by immunofluorescence using specific rabbit
the colloidal iron staining (Fig. 9C, D). However, in other
biopsies, the reduction in colloidal iron staining persisted de-
spite heparin treatment.
Deposits of HuPlt CP and/or NCP antigens were never
detected in the glomeruli from normal subjects or from patients
with Berger's glomerulonephritis. These glomeruli always pre-
sented a normal pattern of colloidal iron staining. No deposits
of HuPit CP and NCP were detectable in renal tissues obtained
from six nephrotic patients with minimal glomerular disease. In
these tissues there was a marked reduction of colloidal iron
staining. Deposits of HuPlt CP were detected in the GCW of
two patients with minimal glomerular disease. These deposits
were associated with presence of platelets in the lumen of
glomerular capillaries.
Discussion
We have purified HuPit CP from human platelets and pro-
duced an anti-HuPit CP serum in order to evaluate in vitro the
binding of HuPlt CP to normal human renal structures, and in
vivo the localization of HuPit CP to glomeruli of patients with
SLE glomerulonephritis. The cationic protein fraction (p1 10.5)
obtained after acid extraction from sonicated whole human
platelets was shown to be composed by three types of CP with
an apparent molecular weight of 55 to 60, 40 to 45 and 10 to 15
kd as determined by HPLC or SDS-PAGE. Of the three
molecular types, the 40 to 45 kd and especially the 10 to 15 kd
proteins were, on a molar basis, most effective in increasing the
permeability of skin vessels. The isoelectric point of the 30 kd
vascular permeability factor described by Nachman, Weksler
and Fabris [11] was not determined. However, on the basis of
the biological activity this factor may correspond to our 40 to 45
kd fraction. The differences in molecular weight between the
preparations of Nachman et al [11] and those obtained in our
laboratory, probably reflect differences in extraction and puri-
fication procedures as well as differences in techniques used in
determination of the molecular weight. The 40 to 45 kd and the
10 to 15 kd fractions shared similar properties with "platelet
derived growth factor" [391 and "platelet basic protein" [40],
respectively. The anti-HuPit CP serum used in this study
specifically recognized at least the 55 to 60 and 40 to 45 kd
HuPit CP fractions, as shown by a radiometric assay as well as
by the immunoprecipitation analysis on SDS-PAGE of 125j
HuPIt CP eluted by HPLC and of the 1251-whole human platelet
Table 2. Detection of HuPIt CP and NCP deposits as well as evaluation of colloidal iron staining in glomeruli from patients with SLE
glomerulonephritis categorized according to clinical activity
Histo-
Protein-
uria Grade
Immunofluorescence
Hu-
Reduction of colloidal
iron staining"
After
logic Nephrotic g124 Activ- Pit Seg- heparin
Patients classa syndrome hr ity IgG" 1gM IgA C3 Clq C4 F CPC NCPe Total mental %
1)C.A. I no 0.5 III 0 0 0 0 0 00 0 0 0/5 0/5 0
2)S.E. II no 0 III +3 0 0 +3 +3 0 +2 +1 +1 16/33 9/33 90
3) P.G. II no 3.4 III +1 0 +1 +2 +2 +1 +2 0 0 0/5 0/5 ND.
4) C.P. 111 no 2.2 II + I + 1 0 + 2 + 2 0 + 1 + I + 1 18/19 1/19 80
5)M.M. IV yes 4.2 1 +2 +1 +1 +2 +3 +1 +2 +1 +1 27/29 1/29 90
6)V.C. IV yes 3.8 11 +3 +1 +1 +1 +3 +1 0 +2 0 0/5 0/5 N.D.
7) B.M. IV yes 6.5 II +2 +2 + 1 + 1 +2 0 0 +3 +2 1/4 2/4 ND.
8)P.A. IV yes 4.8 1 +3 +2 +3 +2 +2 +2 +2 +3 +1 3/23 17/23 60
9)V.E. IV yes 4.5 I +3 +2 +3 +3 +2 +2 +2 +3 +2 1/5 4/5 ND.
10) C.C. IV no 2.8 I +2 + 1 + I + 1 + 1 + 1 +2 +2 0 1/6 1/6 N.D.
11) C.G. V yes 4.4 II +3 + 1 0 +2 + 1 0 +2 + 1 0 2/17 9/17 90
12)C.C. V yes 8.1 II +3 +2 +2 +2 +3 +2 +1 +1 +1 31/34 1/34 100
13) M.A. V yes 6.1 1 +3 +2 +2 +3 + 1 +2 + 1 +2 + 1 27/30 3/30 ND.
14)G.M. V yes 10.1 I +3 0 0 +1 +1 0 +1 +3 +1 0/24 18/24 N.D.
Controls
Berger's — no <0.5 — +'/ 0 +2/3 +2/3 0 0 + 1 0 0 1/28 4/28 —
GN (6)
Minimal — yes 8.3±4.2 — 0 0 0 0 0 0 0 OI+2 0 50/64 10/65 100
glomerular
disease (8)
Normal — no <0.5 — 0 0 0 0 0 0 0 0 0 0/89 0/89 —
human
kidney (8)
Classification according to Appel et al (37).
b Glomerular deposits of human IgG, 1gM, IgA,
antisera (Behrinwerke).
HuPIt CP and NCP were detected by immunofluorescence using specific goat anti-HuPIt CP and rabbit anti-NCP sera.
d The colloidal iron staining [361, was used to evaluate by light microscopy the loss of GPA. Results were expressed as the number of glomeruli
with either total or segmental loss of GPA on the total number of glomeruli. Colloidal iron staining was also performed in sections following
incubation with heparin. Results were expressed as the % of glomeruli with a normal pattern of colloidal iron staining. Superimposable results were
obtained when using a high ionic strength (NaCI Ito 3 M) buffer (0.1 M phosphate).
Range of scores.
Deposits of HuPlt CP were detected in the GCW of two out of eight patients with minimal glomerular disease.
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Fig. 7A. In vitro binding of IJuPIt CP to normal, human, renal cortical tissue. Strong staining of the GCW, the mesangium and the peritubular
capillaries is seen. B. 'In vitro' loss of GPA. Marked reduction of colloidal iron staining after incubation of normal, human renal cortical tissue
with HuPIt CP. C. Colloidal iron staining in the normal portion of a kidney obtained at nephrectomy from a patient with renal carcinoma. D.
Restoration of GPA. The normal pattern of the colloidal iron staining was restored in HuPIt CF-treated sections of normal human renal cortex
following incubation with heparin or with a high ionic strength (NaCI Ito 3M) butler (0.1 M phosphate). (A x212; B,C,D x340)
Fig. 8. In vivo binding of HuPlt CP to GCW of patients with SLE glomnerulonephritis. intense staining was observed in glomeruli from patients
No. 9 (A) and 14 (B) (Table 2). (x300).
extract. Reaction of the anti-HuPIt CP serum with other con- sections of normal human kidney; and second, that abnormal
taminant antigenic components was not observed, deposits of HuPIt CP were present in glomeruli of patients with
The results obtained using the anti-HuPit CP serttm showed, SLE glorneruloncphritis, the latter changes resulting from an in
first, that HuPIt CP bound in vitro to the GCW, and to a lesser vivo binding of HuPlt CP to the GCW of these patients.
degree to the mesangium and the peritubular capillaries, in Ihe in vitro binding of HuPlt CP to structures contained in
4
SI-
'I
B,
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Fig. 9. In vivo loss of GPA. Segmental (A) and total (B) reduction of the colloidal iron staining in two SLE patients (No. 9 and 14, Table 2), with
grade I, nephrotic syndrome. Deposits of HuPit CP and NCP were present in the GCW of these two patients. C and D Restoration of the colloidal
iron staining after incubation of tissue sections with heparin.
sections of normal human kidney was ionic in nature since
heparin, when added simultaneously, prevented the binding of
HuPIt CP to the renal structures. In addition heparin, when
added after FluPit CP, as well as a high molarity buffer, was able
to remove the HuPIt CP bound in vitro to normal kidney
sections. The in vitro binding of HuPlt CP to GCW was
associated with a reduction in the ability of renal tissue to react
with colloidal iron. This qualitative staining for GPA mainly
detects epithelial cell surface sialoglycoproteins. The glomeru-
lar basement membrane anionic sites are also stained, but this
reaction probably contributes little to the overall blue staining.
The reduction in staining could result from an ionic neutraliza-
tion of GPA or from an enzymatic degradation of heparan
sulfate by a platelet derived heparinase [41]. Heparan sulfate is
the main constituent of GPA [42]. Though the enzymatic
activity of HuPlt CP was not studied the reduction of colloidal
iron staining appeared related to an ionic neutralization of GPA
since aprotin, a protease inhibitor [38], did not prevent the
decrease, while heparin restored the colloidal iron staining. In
contrast, the normal pattern of colloidal iron staining was only
partially restored by heparin when platelets were directly
stimulated on renal section with IC or PAF, suggesting that
platelet secretory components other than HuPit CP might
account for a concomitant enzymatic degradation of GPA.
In glomeruli of patients with SLE, the intensity and extent of
HuPIt CP detected by immunofluorescence was directly pro-
portional to the grade of the disease, but was not correlated
with the histologic class of SLE changes. The deposition of
HuPit CP in GCW exceeded that of NCP. Conceivably, the
deposits of HuPlt CP were not the consequence of the auto-
immune process per Se, but rather resulted from an in vivo
activation of platelets with release of their granule constituents
[43] triggered either by direct interaction with IC [43, 44] or by
PAF generated from stimulated leukocytes [32, 45]. This inter-
pretation is supported by the observation that deposits of HuPlt
CP are present in other types of glomerulonephritis, such as
membranous and membranoproliferative glomerulonephritis
and focal segmental glomerulosclerosis (unpublished results).
In these diseases shortened platelet survival, intrarenal seques-
tration of platelets and/or glomerular localization of platelet
related antigens and PF4 have been shown [3—9]. Furthermore,
it is unlikely that the deposition of HuPlt CP in GCW of SLE
patients was the mere consequence of proteinuria since circu-
lating HuPlt CP were not detectable in normal plasma. In
addition, deposits of HuPIt CP were not found in glomeruli
present in renal tissues obtained from the majority of patients
with minimal glomerular disease. It is well established that in
these glomeruli the GPA stainable by colloidal iron are de-
creased, a phenomenon that probably cannot be ascribed to
neutralization of GPA by HuPlt CP or NCP.
>, Vfp
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As observed in the experiments performed in vitro on section
of normal human kidney, heparin treatment of sections of renal
tissue from patients with SLE removed the HuPlt CP hound in
vivo to the glomeruli of these patients, and also restored the
normal colloidal iron staining pattern. These results suggest that
the reduction in GPA present in renal tissues of SLE patients
was due, at least in part, to an ionic interaction of HuPlt CP
with GPA. Since only light microscopy was used, the present
studies do not address the question as to which arc the precise
sites of binding of HuPIt CP to the GCW. In addition, the
qualitative techniques employed to evaluate the localization of
HuPIt CP in the GCW and the reduction in GPA cannot
demonstrate whether or not the HuPIt CP play a primary role in
proteinuria. This information might only be obtained from
further studies in which an increase in plasma levels and/or
urinary excretion of HuPIt CP is correlated with the degree of
proteinuria and the number of anionic sites detectable in the
glomerular basement memhrane by quantitative techniques. In
conclusion, the results of the present study indicate that bio-
logically active HuPlt CP may bind to human GCW and may
also contribute to the progression of glomerular disease by
recruitment of inflammatory cells [11, 46] and/or by stimulation
and proliferation of resident glomerular cells [47, 48].
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